192
Participants
Start Date
March 31, 2014
Primary Completion Date
March 31, 2016
Study Completion Date
September 30, 2017
Sequential Icotinib Plus Chemotherapy
Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
Icotinib
Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
ACTIVE_NOT_RECRUITING
First Affiliated Hospital of Zhengzhou University, Zhengzhou
ACTIVE_NOT_RECRUITING
General Hospital of Guangzhou Military Command, Guangzhou
ACTIVE_NOT_RECRUITING
Cancer Hospital of Sun Yat-sen, Guangzhou
ACTIVE_NOT_RECRUITING
First Affiliated Hospital of Guangzhou Medical College, Guangzhou
ACTIVE_NOT_RECRUITING
The university of Hong Kong-Shenzhen Hospital, Shenzhen
ACTIVE_NOT_RECRUITING
Shenzhen People's Hospital, Shenzhen
ACTIVE_NOT_RECRUITING
Medical Oncology,Shenzhen Second People's Hospital, Shenzhen
ACTIVE_NOT_RECRUITING
Thoracic Surgery,Shenzhen Second People's Hospital, Shenzhen
ACTIVE_NOT_RECRUITING
Peking University Shenzhen Hospital, Shenzhen
ACTIVE_NOT_RECRUITING
Guangdong Agribusiness Center Hospital, Zhanjiang
ACTIVE_NOT_RECRUITING
Jiangmen central hospital, Jiangmen
ACTIVE_NOT_RECRUITING
First Affiliated Hospital of Guangxi Medical University, Nanning
ACTIVE_NOT_RECRUITING
Hainan Provincal Nong Ken Hospital, Haikou
ACTIVE_NOT_RECRUITING
Hainan Provincial People's Hospital, Haikou
ACTIVE_NOT_RECRUITING
Shaanxi province people's hospital, Xi’an
ACTIVE_NOT_RECRUITING
Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an
ACTIVE_NOT_RECRUITING
Xi'an Chang'an Hospital, Xi’an
RECRUITING
Tangdu Hospital，Fourth Military Medical University, Xi’an
ACTIVE_NOT_RECRUITING
First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
ACTIVE_NOT_RECRUITING
Shanxi Cancer Hospital, Xi’an
ACTIVE_NOT_RECRUITING
Baoji Central Hospital, Baoji
ACTIVE_NOT_RECRUITING
3201 Hospital, Hanzhong, Shanxi, Hanzhong
ACTIVE_NOT_RECRUITING
First Hospital of Lanzhou University, Lanzhou
ACTIVE_NOT_RECRUITING
Lanzhou military region general hospital, Lanzhou
ACTIVE_NOT_RECRUITING
Medical Oncology，General Hospital of Ningxia Medical University, Yinchuan
ACTIVE_NOT_RECRUITING
Radiation Oncology，General Hospital of Ningxia Medical University, Yinchuan
ACTIVE_NOT_RECRUITING
Respiratory medicine，General Hospital of Ningxia Medical University, Yinchuan
ACTIVE_NOT_RECRUITING
Urumqi General Hospital of Lanzhou Military Region General Hospital, Ürümqi
ACTIVE_NOT_RECRUITING
Xinjiang medical university affiliated tumor hospital, Ürümqi
ACTIVE_NOT_RECRUITING
First Affiliated Hospital of Xinjiang Medical University, Ürümqi
ACTIVE_NOT_RECRUITING
Autonome Region Xinjiang Uygur Chinese medicine hospital, Ürümqi
Lead Sponsor
Betta Pharmaceuticals Co., Ltd.
INDUSTRY